A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine

Cardiovascular diseases are the leading cause of death worldwide. Discovering new therapies to treat heart disease requires improved understanding of cardiac physiology at a cellular level. Extracellular vesicles (EVs) are plasma membrane‐bound nano‐ and microparticles secreted by cells and known to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karl T. Wagner, Milica Radisic
Formato: article
Lenguaje:EN
Publicado: Wiley-VCH 2021
Materias:
Acceso en línea:https://doaj.org/article/7c9a275171c2487d98971ea80d426150
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7c9a275171c2487d98971ea80d426150
record_format dspace
spelling oai:doaj.org-article:7c9a275171c2487d98971ea80d4261502021-11-06T04:12:26ZA New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine2699-930710.1002/anbr.202100047https://doaj.org/article/7c9a275171c2487d98971ea80d4261502021-11-01T00:00:00Zhttps://doi.org/10.1002/anbr.202100047https://doaj.org/toc/2699-9307Cardiovascular diseases are the leading cause of death worldwide. Discovering new therapies to treat heart disease requires improved understanding of cardiac physiology at a cellular level. Extracellular vesicles (EVs) are plasma membrane‐bound nano‐ and microparticles secreted by cells and known to play key roles in intercellular communication, often through transfer of biomolecular cargo. Advances in EV research have established techniques for EV isolation from tissue culture media or biofluids, as well as standards for quantitation and biomolecular characterization. EVs released by cardiac cells are known to be involved in regulating cardiac physiology as well as in the progression of myocardial diseases. Due to difficulty accessing the heart in vivo, advanced in vitro cardiac “tissues‐on‐a‐chip” have become a recent focus for studying EVs in the heart. These physiologically relevant models are producing new insight into the role of EVs in cardiac physiology and disease while providing a useful platform for screening novel EV‐based therapeutics for cardiac tissue regeneration post‐injury. Numerous hurdles have stalled the clinical translation of EV therapeutics for heart patients, but tissue‐on‐a‐chip models are playing an important role in bridging the translational gap, improving mechanistic understanding of EV signaling in cardiac physiology, disease, and repair.Karl T. WagnerMilica RadisicWiley-VCHarticlecardiomyocytesexosomesextracellular vesiclesheartmyocardiumregenerationBiotechnologyTP248.13-248.65Medical technologyR855-855.5ENAdvanced NanoBiomed Research, Vol 1, Iss 11, Pp n/a-n/a (2021)
institution DOAJ
collection DOAJ
language EN
topic cardiomyocytes
exosomes
extracellular vesicles
heart
myocardium
regeneration
Biotechnology
TP248.13-248.65
Medical technology
R855-855.5
spellingShingle cardiomyocytes
exosomes
extracellular vesicles
heart
myocardium
regeneration
Biotechnology
TP248.13-248.65
Medical technology
R855-855.5
Karl T. Wagner
Milica Radisic
A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine
description Cardiovascular diseases are the leading cause of death worldwide. Discovering new therapies to treat heart disease requires improved understanding of cardiac physiology at a cellular level. Extracellular vesicles (EVs) are plasma membrane‐bound nano‐ and microparticles secreted by cells and known to play key roles in intercellular communication, often through transfer of biomolecular cargo. Advances in EV research have established techniques for EV isolation from tissue culture media or biofluids, as well as standards for quantitation and biomolecular characterization. EVs released by cardiac cells are known to be involved in regulating cardiac physiology as well as in the progression of myocardial diseases. Due to difficulty accessing the heart in vivo, advanced in vitro cardiac “tissues‐on‐a‐chip” have become a recent focus for studying EVs in the heart. These physiologically relevant models are producing new insight into the role of EVs in cardiac physiology and disease while providing a useful platform for screening novel EV‐based therapeutics for cardiac tissue regeneration post‐injury. Numerous hurdles have stalled the clinical translation of EV therapeutics for heart patients, but tissue‐on‐a‐chip models are playing an important role in bridging the translational gap, improving mechanistic understanding of EV signaling in cardiac physiology, disease, and repair.
format article
author Karl T. Wagner
Milica Radisic
author_facet Karl T. Wagner
Milica Radisic
author_sort Karl T. Wagner
title A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine
title_short A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine
title_full A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine
title_fullStr A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine
title_full_unstemmed A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine
title_sort new role for extracellular vesicles in cardiac tissue engineering and regenerative medicine
publisher Wiley-VCH
publishDate 2021
url https://doaj.org/article/7c9a275171c2487d98971ea80d426150
work_keys_str_mv AT karltwagner anewroleforextracellularvesiclesincardiactissueengineeringandregenerativemedicine
AT milicaradisic anewroleforextracellularvesiclesincardiactissueengineeringandregenerativemedicine
AT karltwagner newroleforextracellularvesiclesincardiactissueengineeringandregenerativemedicine
AT milicaradisic newroleforextracellularvesiclesincardiactissueengineeringandregenerativemedicine
_version_ 1718443926293053440